Results 171 to 180 of about 196,164 (338)

Bendamustine and Rituximab Treatment, Chronic Lymphocytic Leukemia, Direct Antiglobulin Test, and False Negatives

, 2019
Won Sriwijitalai, Viroj Wiwanitkit
openalex   +1 more source

Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia [PDF]

, 2006
Partow Kebriaei, Rima M. Saliba, Carrie Ma, Cindy Ippoliti, Daniel R. Couriel, Marcos de Lima, Sergio Giralt, Muzaffar H. Qazilbash, James Gajewski, Chul S. Ha, Richard E. Champlin, Issa F. Khouri   +11 more
openalex   +1 more source

Rituximab Downregulates Gene Expression Associated with Cell Proliferation, Survival, and Proteolysis in the Peripheral Blood from Rheumatoid Arthritis Patients: A Link between High Baseline Autophagy-Related ULK1 Expression and Improved Pain Control [PDF]

, 2016
Elena V. Tchetina, Anastasya N. Pivanova, G. A. Markova, G. Lukina, Е Н Александрова, А. П. Алексанкин, С. А. Макаров, A. N. Kuzin   +7 more
openalex   +1 more source

Disease progression more than 6 years after treatment impacts overall survival in mantle cell lymphoma

International Journal of Cancer, EarlyView.
What's New? Patients with mantle cell lymphoma showing disease progression within 24 months of primary treatment have worse prognosis than patients with later progression. This population‐based study suggests that although early relapse is especially serious, disease progression more than 6 years after treatment still leads to worse survival than the ...
Sara Ekberg, Ingrid Glimelius, Alexandra Albertsson‐Lindblad, Karin E. Smedby, Mats Jerkeman, Caroline E. Dietrich   +5 more
wiley   +1 more source

Early posttransplant rituximab use in kidney transplant recipients with preexisting donor-specific antibodies. [PDF]

Ren Fail
Yamauchi J, Fornadi K, Raghavan D, Jweehan D, Oygen S, Marineci S, Pole A, Jain D, Lazar-Molnar E, Molnar MZ.   +9 more
europepmc   +1 more source

Targeting CD20 in Primary Membranous Nephropathy Serologically and Histologically Negative for PLA2R: Is Obinutuzumab Superior to Rituximab?

Huiling Cao, Yu-Mei Feng, Xueting Li, Ben Ke, Limin Gong   +4 more
openalex   +2 more sources

Anti‐NMDA receptor autoimmune encephalitis associated with ovarian teratoma: A case series and literature review

International Journal of Gynecology &Obstetrics, Volume 169, Issue 1, Page 23-30, April 2025.
Abstract Autoimmune encephalitis is a group of disorders characterized by symptoms of dysfunction of the limbic and extra‐limbic systems that occur in association with antibodies against intracellular antigens, synapses, or proteins located on the surface of nerve cells. Anti‐NMDA (N‐methyl‐D‐aspartate) receptor encephalitis was first described in 2007
Pham Ba Nha, Nguyen Phuong Tu, Nguyen Viet Ha, Duong Thi Thu Hien, Nguyen Thi Thu Phuong, Nguyen Anh Son, Nguyen Tien Hoang   +6 more
wiley   +1 more source

Early Low-Dose Rituximab for Mild-to-Moderate Thyroid Eye Disease: A Preliminary Evaluation of Efficacy and Safety. [PDF]

Int J Endocrinol
Lu M, Wang L, Zhang X.
europepmc   +1 more source

Therapy of Steroid-Refractory Chronic GVHD with Subcutaneous Low-Dose Alemtuzumab and Rituximab Combination Is Effective and Safe

, 2012
Cesar Homero Gutiérrez‐Aguirre, Olga Graciela Cantú‐Rodríguez, Óscar González‐Llano, José Carlos Jaime‐Pérez, Consuelo Mancías‐Guerra, Juan Antonio Flores‐Jiménez, Julio Alatorre‐Ricardo, David Gómez‐Almaguer   +7 more
openalex   +1 more source

Long-term treatment patterns and outcomes in IgG4-related disease - a retrospective single-center cohort study focusing on rituximab. [PDF]

Rheumatol Int
Hammitzsch A, Ferraro N, Bachmann Q, Heemann U, Moog P.   +4 more
europepmc   +1 more source